Harrow Sample Contracts
SNAP-IT APP END-USER LICENCE AGREEMENTEnd User License Agreement • November 25th, 2019 • Harrow
Contract Type FiledNovember 25th, 2019 JurisdictionWe only use any personal data we collect through your use of the App and the Services in the ways set out in our privacy policy https://www.snap-it.app/privacy-policy.php.
MILESTONE PAYMENT AGREEMENTMilestone Payment Agreement • October 1st, 2025 • Harrow, Inc. • Pharmaceutical preparations • Harrow
Contract Type FiledOctober 1st, 2025 Company Industry JurisdictionThis MILESTONE PAYMENT AGREEMENT (this “Agreement”), dated as of September 24, 2025, is entered into by and among HARROW, INC., a Delaware corporation (“Harrow”) and Donald Bradford Osborne, solely in his capacity as representative of the former stockholders of Melt Pharmaceuticals, Inc. (“Stockholder Representative”). Capitalized terms used but not defined in this Agreement will have the meanings assigned to them in the Merger Agreement (as defined below).
Graydon Terms and conditions EULAEnd User License Agreement (Eula) • February 21st, 2019 • Harrow
Contract Type FiledFebruary 21st, 2019 JurisdictionThis licence agreement (Licence) is a legal agreement between you (Customer) and TruNarrative Limited (“TruNarrative”), whose registered office is at The Leeming Building, Vicar Lane, Leeds, LS2 7JF, United Kingdom (TruNarrative) for certain software applications and platforms which it makes available to subscribers via the internet on a pay-per-use basis for the purpose and online documentation.
LICENSE AGREEMENT BY AND BETWEEN WAKAMOTO PHARMACEUTICAL CO., LTD. AND HARROW HEALTH, INC. AUGUST 18, 2021 LICENSE AGREEMENTLicense Agreement • November 9th, 2021 • Harrow Health, Inc. • Pharmaceutical preparations • Harrow
Contract Type FiledNovember 9th, 2021 Company Industry JurisdictionThis License Agreement (this “Agreement”) is made effective as of the day of August, 2021 (the “Effective Date”) by and between Wakamoto Pharmaceutical Co., Ltd. Japanese corporation having its principal place of business at 2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8330, Japan, including its Affiliates (“Wakamoto”), and Harrow Health, Inc., a Delaware corporation having its principal place of business at 102 Woodmont Blvd., Suite 610, Nashville, TN 37205 USA, including its Affiliates (“Harrow”). Wakamoto and Harrow are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”